Thyroxine
Phase 2Small molecule
Thyroxine is one of 70 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.
3
Indications
12
Total Trials
1
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
145 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1DWP16001
Daewoong Pharmaceutical Co. LTD.Phase 3
Maridebart Cafraglutide
AmgenPhase 3
Retatrutide
Eli LillyPhase 3
Elecoglipron
AstraZenecaPhase 3
Imeglimin
PPoxel SA
Phase 3
Ganagliflozin
HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
Dorzagliatin
HHua Medicine Limited
Phase 3
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Thyroxine
WWashington University School of Medicine
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypothyroidism2 trials
Effect of Acupuncture and Low Caloric Diet on Primary Hypothyroidism and Irregular Menstruation in Infertile Women
Completed·—·Phase 2·NCT05804149·60 enrolled
Thyroiditis1 trial
The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis
Completed·—·Phase 2·NCT03289403·194 enrolled
Treatment1 trial
Supplemental Thyroxine Treatment for Preterm Infants With Hypothyroxinemia
Completed·—·N/A·NCT00565890·100 enrolled
Type 2 Diabetes Mellitus1 trial
The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.
Completed·—·N/A·NCT02509858·33 enrolled
Papillary Thyroid Carcinoma1 trial
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
Recruiting·—·Phase 2·NCT06087068·140 enrolled
6 more indications
Hemorrhage1 trial
Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage
Withdrawn·—·Phase 3·NCT03390530
Severe Acute Respiratory Syndrome1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Thyroxine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details